- Conditions
- Cervical Cancer
- Interventions
- Clinic Outreach, Enhanced Outreach, Low-Touch Strategy, High-Touch Strategy
- Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 899
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer
- Interventions
- THEO
- Other
- Lead sponsor
- Regenstrief Institute, Inc.
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
- Interventions
- ATV-1601, ATV-1601 + Fulvestrant
- Drug · Combination Product
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more
- Conditions
- Cervical Cancer, Precancerous Condition
- Interventions
- pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cervical Cancer
- Interventions
- preventative dietary intervention
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Cervical Cancer
- Interventions
- Discussion & scoring of health states related to the treatment of cervical cancer
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Solid Tumors
- Interventions
- RMC-5552
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 5 more
- Conditions
- Cervical Cancer, Papilloma Viral Infection
- Interventions
- Stage 1 SOC, Stage 1 HERS, Stage 2 HERS, Stage 2 HERS+HC, Stage 3 SOC, Stage 3 HERS, Stage 3 HERS+HC, Stage 4 HERS, Stage 4 HERS+HC
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 546 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasias, Digital Colposcopy, Precancerous Cervical Lesions
- Interventions
- Diagnostic imaging aid for one-visit management of cervical lesions
- Device
- Lead sponsor
- Brookdale University Hospital Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Colorectal Cancer Screening, Cervical Cancer Screening
- Interventions
- Self-sampling HPV test, Fecal occult blood test
- Diagnostic Test
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 50 Years to 65 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma, Bladder Cancer
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- EF5
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
- Interventions
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
- Conditions
- Papillomavirus Infections
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- IMRT with tomotherapy
- Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder, Cancer of Cervix, Cancer of Colon, Cancer of Rectum, Cancer of Esophagus, Cancer of Gallbladder, Cancer of Liver, Cancer of Ovary, Cancer of Pancreas, Cancer of Prostate, Cancer of Kidney and Renal Pelvis, Cancer of Stomach, Cancer of Testis, Cancer of Uterus, Cancer of Uterus and Cervix, Cancer of Kidney
- Interventions
- Not listed
- Lead sponsor
- DxTerity Diagnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Compton, California • Bradenton, Florida • Fort Myers, Florida + 1 more
- Conditions
- Cervical Cancer
- Interventions
- Treatment with Electronic Brachytherapy
- Device
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Cervical Cancer, Diarrhea, Prostate Cancer, Radiation Toxicity, Sarcoma
- Interventions
- dietary intervention, management of therapy complications, quality-of-life assessment
- Dietary Supplement · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cervical Cancer, Uterine Cancer
- Interventions
- 18F fluciclovine, 18F fluciclovine PET
- Drug · Device
- Lead sponsor
- Nghi Nguyen
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
- Interventions
- Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral
- Other · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cervical Cancer
- Interventions
- celecoxib, cisplatin, fluorouracil, brachytherapy, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Burlingame, California + 30 more
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- gefitinib, immunohistochemistry staining method, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy, sentinel lymph node biopsy
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Central Nervous System Neoplasm, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hodgkin Lymphoma, Malignant Bone Neoplasm, Malignant Brain Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Non-Hodgkin Lymphoma, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Cervical Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Differentiated Thyroid Gland Carcinoma AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage I Thyroid Gland Medullary Carcinoma AJCC v8, Stage I Uterine Corpus Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA Uterine Corpus Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Differentiated Thyroid Gland Carcinoma AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Thyroid Gland Medullary Carcinoma AJCC v8, Stage II Uterine Corpus Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8
- Interventions
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Cervical Cancer
- Interventions
- GSK1120212 (trametinib), GSK2141795
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts